Skip to main content

Ionis Pharmaceuticals(IONS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low73.15
Day High75.16
Open:73.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Ionis Pharmaceuticals

Select a category then submit the form to load news
Tipranks
Ionis Pharmaceuticals (IONS) Receives a Buy from H.C. Wainwright
Tipranks
Jefferies Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Spyre Therapeutics (SYRE) and Ionis Pharmaceuticals (IONS)
Tipranks
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
Zacks Investment Research
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
Tipranks
Ionis Ends Early-Stage Hero Study in Down Syndrome Alzheimer’s Risk: What Investors Should Know
GlobeNewswire
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Motley Fool
What a $20 Million Bet on a Stock Down 3% Signals for Investors
Motley Fool
Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Anavex Life Sciences (AVXL), Cytokinetics (CYTK)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Progyny (PGNY), Ionis Pharmaceuticals (IONS)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Ionis Pharmaceuticals (IONS)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)
Tipranks
Ionis Pharmaceuticals (IONS) Gets a Buy from Bank of America Securities
Tipranks
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Ionis Pharmaceuticals (IONS) and DENTSPLY SIRONA (XRAY)
Tipranks
Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein
Tipranks
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), CVRx (CVRX)
GlobeNewswire
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Tipranks
Ionis Advances Bepirovirsen After Positive Phase 3 Results
Tipranks
Ionis Pharmaceuticals (IONS) Gets a Buy from Bank of America Securities
Tipranks
RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Tipranks
Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Tipranks
Bank of America Securities Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
Tipranks
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS)
Tipranks
Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein
Tipranks
Ionis Pharmaceuticals Completes $770M Convertible Notes Offering
GlobeNewswire
Biogen Completes Acquisition of Alcyone Therapeutics
Business Wire
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Business Wire
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Profile

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.